The Newcastle upon Tyne Hospitals
NHS Foundation Trust

Northern Genetics Service
International Centre for Life
Central Parkway
Newcastle upon Tyne
NE1 3BZ
Tel: 0191 241 8600

Participant Information Sheet

Study Title:	An AAV8 Neutralizing Antibody Seroprevalence Study in Subjects with Late Onset Pompe Disease
Protocol Number:	AT100-01
Protocol Version:	1.1
ICF Version:	1.1
Investigational Product:	NA
Indication:	Late Onset Pompe Disease

Principal Investigator (study doctor):

Name: Professor Jorge Diaz Manera
Address: The Newcastle upon Tyne Hospitals NHS Foundation Trust
International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ
Tel: 0191 241 8602
Out of hours emergency contact: The Newcastle upon Tyne Hospitals NHS Foundation Trust
Switchboard: 0191 233 6161

You are being asked to take part in a clinical research study being sponsored by Audentes Therapeutics Inc. (Sponsor) to assess how often people with Late Onset Pompe Disease have antibodies to a virus known as AAV8. Clinical research studies are those research studies which include only people who freely choose to take part. Please take your time to read this information carefully. It is important that you read and understand the contents of this participant information sheet.

This participant information sheet gives you important information about the study to help you decide if you want to participate. It describes the purpose of this study, the study procedures, the possible risks and benefits, the amount of time required for the study, and provides information about your rights as a study participant. Your consent is required for participation.

If you are unsure of anything within this participant information sheet, or if you have any questions or queries please discuss this with your study team. You can also discuss this participant information sheet with family or friends or your primary care or specialist doctor before making your decision to take part in this study. If you decide you would like to take part in this study, you will be asked to complete the informed consent form.

Your permission to take part in this study is voluntary. You are free to say yes or no. If you do not want to participate, your regular medical care and legal rights will not be affected. Even if you join this study, you may stop your participation at any time and your regular medical care and legal rights will not be affected.

1. WHAT YOU SHOULD KNOW ABOUT THIS STUDY

1.1 Why is this study being done?

The Sponsor of this study is developing a potential gene therapy treatment for patients who have Pompe Disease. Gene therapy is the introduction of normal genes into cells to correct genetic disorders.

Genes are found inside cells, and new genes cannot be introduced inside the cell without help. In this case, the help is in the form of a very small and simple virus called adeno-associated virus (AAV). The AAV virus is not known to cause any disease or illness in the human body. In everyday life, people are exposed to this type of virus. When you have been exposed to the virus, the body may recognize the virus as a foreign substance and create antibodies against the virus. The gene therapy being developed by the Sponsor uses AAV serotype 8 (AAV8) as the carrier virus for the gene therapy. The Sponsor would like to test a random group of patients with Late Onset Pompe disease to see how often antibodies to AAV8 occur through natural exposure to the virus.

1.2 Why have I been asked to take part?

You have been invited to participate in this research study because you have Late Onset Pompe Disease (LOPD).

1.3 How many people will take part in this study?

Up to 60 people are expected to be in this study in approximately 8 locations in North America and Europe.

1.4 How long is participation in this study?

If you decide to take part in the study, you will sign an Informed Consent Form allowing the study team to review your medical records to confirm your medical history and then to collect a single blood sample. Generally, this will not exceed a single day.

1.5 Can you stop participating in the study?

You are free to stop taking part in this study at any time. If you decide you do not want to be in the study anymore, you will not lose any medical benefits except the test that you might have been receiving only for this study. Also, even if you do leave the study, all information and samples collected from you before you stop the study may still be used by the Sponsor to understand more about AAV8 antibodies in patients with Pompe Disease.

If you want to stop being part of the study, please inform a member of the study team.

The study doctor or Sponsor may stop your participation at any time without your permission. The study doctor will tell you if this happens. Some of the reasons this could happen include:

- You are not able to complete the study procedures as needed

- The study is stopped by the Sponsor for reasons not related to you

There may be other reasons to stop your participation in this study that we do not know about now.

1.6 Whom should you contact if you have questions?

If you have a question, concern or complaint about any part of this study, you may contact the study doctor, or any member of the study team, who will do their best to help.

If you have any questions about your rights as part of the study, or any concerns or complaints about the study that you do not want to discuss with the study doctor or study team, contact the **Patient Advice and Liaison Service (PALS) on**
Freephone: 0800 0320202
Text: 0781 5500015
Email: northoftynepals@nhct.nhs.uk

1.7 Are there any benefits to taking part in this study?

Being in this study will have no impact on your condition. However, being in this study may benefit doctors to learn more about AAV8 antibodies in patients with Late Onset Pompe Disease.

2. WHAT WILL HAPPEN IF YOU PARTICIPATE IN THE STUDY

2.1 What am I expected to do if I take part in the study?

If you agree to take part in this study, you will be asked to sign a separate Informed Consent Form, and you must meet specific entry requirements before being allowed to participate in the study.

If you decide to be in this study, you will be expected to:

- Supply complete information about your medical and medication history
- Provide a blood sample

2.2 What can I say to others if I take part in the study?

In all clinical studies, it is important that the people participating in the study (doctors, nurses, and study participants) do not make any conclusions about what the results of the study might be until all the data has been collected and reviewed. If you participate in this clinical study, you should feel free to discuss the study with your family and with other people who are close to you. If you have questions of any sort, please talk to the study team.

2.3 What tests or procedures will take place and at what time?

2.3.1 Screening and blood collection (Day 1)

The Screening and blood collection will take place on the same day.

1. Review of your general health (including a review of current illnesses and medications) and medical history
2. 5mL Blood sample collection

To confirm that you can participate in this study, the study team will need to review the following information from your medical records:

1. Diagnosis of Pompe
2. Medication use: The only approved treatment for Pompe disease is enzyme replacement therapy (ERT) with recombinant human GAA (Lumizyme, Myozyme). To be able to take part in this study, you need to have either never received Lumizyme or Myozyme OR have been receiving Lumizyme or Myozyme for at least 2 years and been on a stable dose for the last 6 months.
3. Pulmonary (breathing) function
4. Review of other medical conditions

If you meet all study requirements, you will be given the choice to participate in the study. Some reasons why you would not be able to participate in this study include:

- You do not have a diagnosis of Pompe from a confirmed mutation (mistake) in the GAA gene
- You have received AAV8 gene therapy in the past

2.4 What types of tests or procedures will be involved with this study and what are the risks with these procedures?

As with all procedures, you may experience side effects from the blood collection. You should ask the study team or study doctor if you have questions about having your blood collected.

Blood Samples: The blood sample for this study will be drawn by putting a needle into a vein in your arm. Blood sample will be taken to measure the presence of viral antibodies, which are a normal part of the body's immune defense system.

Blood Draw Risks: Taking blood for the laboratory tests in this study may cause you to have temporary pain from the needle stick, bruising or swelling at the site, and rarely, infection or fainting.

Review of Medications and General Health: You will be asked to supply a list of medications that you take and to review your general health.

2.5 What will happen to my blood sample?

Your blood sample will be collected by a member of the study team, labelled with your unique study code and shipped to an experienced research laboratory in the United States of America (USA) to test for Neutralizing Antibodies for AAV8. Once the test has been completed, any remaining sample will be destroyed.

2.6 What about the costs to participate, and what about expenses and payments?

You will not be charged for taking part in this study, which is outside the normal treatment of your condition. There will be no penalty to you and it will not affect your routine medical care.

You will not receive payment for taking part in this study. You may be reimbursed for reasonable travel, accommodation and food expenses related to participation in this study. This will require submission of receipts for these expenses to the study site or other agreed means of reimbursement.

2.7 What happens if something goes wrong?

If you are injured as a direct result of the study tests, assessments, or any procedures done by the study team in this research study, medical treatment will be provided by the study site.

The Sponsor agrees to follow the guidelines of the Association of the British Pharmaceutical Industry (ABPI) and compensate you if you're injured as a result of taking part in the study – you don't have to prove that your injury was caused by someone's negligence. If you want to read the guidelines, just ask any member of the study team.

The Sponsor will pay compensation where the injury probably resulted from any test or procedure you received as part of the study. Any payment would be without legal commitment. (Please ask if you wish more information on this). The Sponsor would not be bound to pay compensation where the injury resulted from a drug or procedure that was not carried out in line with the study protocol or where the study protocol wasn't followed.

If you have medical insurance, please check with your insurance company that taking part in this study will not affect your policy.

If you are not happy about your treatment and wish to complain, you should contact PALS service at The Newcastle upon Tyne Hospitals NHS Foundation Trust **By phone: 0800 0320 202** or **By email: northoftynepals@nhct.nhs.uk** so that they can advise you about the steps to take as well as being able to give you the contact details for the appropriate people in the hospital.

3. WILL YOUR INFORMATION FROM THIS STUDY BE KEPT CONFIDENTIAL?

Audentes Therapeutics Inc., based in the USA, is the Sponsor for this study. The Sponsor will be using information from your medical records in order to undertake this study and will

act as the data controller for this study. This means that the Sponsor is responsible for looking after your information and using it properly.

Health and care research should serve the public interest, which means that the Sponsor has to demonstrate that this research serves the interests of society as a whole. The Sponsor does this by following the UK Policy Framework for Health and Social Care Research.

As a pharmaceutical company the Sponsor has a legitimate interest in using information relating to your health and care for research studies, when you agree to your taking part in a research study. This means that the Sponsor will use your data, collected in the course of a research study, in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as the Sponsor needs to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, the Sponsor will keep the information about you that it has already obtained. To safeguard your rights, you will be identified by a code that only the study site can link back to you.

If you wish to raise a complaint on how the Sponsor has handled your personal data, you can contact the Sponsor's Data Protection Officer who will investigate the matter. If you are not satisfied with the Sponsor's response or believe the Sponsor is processing your personal data in a way that is not lawful you can complain to the Information Commissioner's Office (ICO). The Sponsor's Data Protection Officer is Antonis Roussos and you can contact him at privacy@astellas.com. The study site will collect information from you for this research study in accordance with the Sponsor's instructions.

The study site will keep your name, [NHS number] and contact details confidential and will not pass this information to the Sponsor The study site will use this information as needed, to contact you about the research study and to oversee the quality of the study. Certain individuals from the Sponsor and regulatory organisations may look at your medical and research records to check the accuracy of the research study. The Sponsor will only receive information without any identifying information. The people who analyse the information will not be able to identify you and will not be able to find out your name, [NHS number] or contact details.

The study site will keep identifiable information about you from this study for 15 years after the study has finished.

When you agree to take part in a research study, the information about your health and care may be provided to researchers running other research studies in this organisation and in other organisations. These organisations may be universities, NHS organisations or companies involved in health and care research in this country or abroad. Your information will only be used by organisations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research.

This information will not identify you and will not be combined with other information in a way that could identify you. The information will only be used for the purpose of health and care research and cannot be used to contact you or to affect your care. It will not be used to make decisions about future services available to you, such as insurance.

Has the study received ethical approval?

All research in the UK is looked at by an independent group of people, called a Research Ethics Committee to protect your interests. This study has been reviewed and given favourable opinion by the Office for Research Ethics Committees Northern Ireland (ORECNI) Research Ethics Committee.

Involvement of the General Practitioner/Family Doctor (GP)

The study team on behalf of the Sponsor would like to inform your general practitioner (GP) or family doctor of your participation in this study; however this is optional and will not impact your participation if you do not agree for your GP/family doctor to be informed.

As there is no treatment, this study will not be registered on any national clinical trial registries.